Neurodegeneration in multiple sclerosis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Axonal loss in multiple sclerosis (MS) is a key component of disease progression and permanent neurologic disability. MS is a heterogeneous demyelinating and neurodegenerative disease of the central nervous system (CNS) with varying presentation, disease courses, and prognosis. Immunomodulatory therapies reduce the frequency and severity of inflammatory demyelinating events that are a hallmark of MS, but there is minimal therapy to treat progressive disease and there is no cure. Data from patients with MS, post‐mortem histological analysis, and animal models of demyelinating disease have elucidated patterns of MS pathogenesis and underlying mechanisms of neurodegeneration. MRI and molecular biomarkers have been proposed to identify predictors of neurodegeneration and risk factors for disease progression. Early signs of axonal dysfunction have come to light including impaired mitochondrial trafficking, structural axonal changes, and synaptic alterations. With sustained inflammation as well as impaired remyelination, axons succumb to degeneration contributing to CNS atrophy and worsening of disease. These studies highlight the role of chronic demyelination in the CNS in perpetuating axonal loss, and the difficulty in promoting remyelination and repair amidst persistent inflammatory insult. Regenerative and neuroprotective strategies are essential to overcome this barrier, with early intervention being critical to rescue axonal integrity and function. The clinical and basic research studies discussed in this review have set the stage for identifying key propagators of neurodegeneration in MS, leading the way for neuroprotective therapeutic development. This article is categorized under: Immune System Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 13×
“MRI remains the standard of care for detecting, diagnosing, and monitoring MS inflammatory activity and neurodegeneration (Thompson et al., 2018).”
BackgroundMethodInfluentialNew diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium, Patsopoulos, N. A., Baranzini, S. E., Santaniello, A., Shoostari, P., Cotsapas, C., Wong, G., Beecham, A. H., James, T., Replogle, J., et al. (2019) · Science · doi:10.1126/science.aav7188 · Cited by 1,818
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Fünfschilling, U., Supplie, L. M., Mahad, D., Boretius, S., Saab, A. S., Edgar, J., Brinkmann, B. G., Kassmann, C. M., Tzvetanova, I. D., Möbius, W., et al. (2012) · Nature · doi:10.1038/nature11007 · Cited by 1,523
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 3×
“Cortical lesions differ from white matter lesions, typically having fewer infiltrating and resident immune cells as well as an intact blood–brain barrier (Junker et al., 2020; Kidd et al., 1999; Peterson et al., 2001).”
BackgroundCohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Matsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Altered human oligodendrocyte heterogeneity in multiple sclerosis
Jäkel, S., Agirre, E., Mendanha Falcão, A., van Bruggen, D., Lee, K. W., Knuesel, I., Malhotra, D., ffrench-Constant, C., Williams, A., & Castelo-Branco, G. (2019) · Nature · doi:10.1038/s41586-019-0903-2 · Cited by 854
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Absinta, M., Maric, D., Gharagozloo, M., Garton, T., Smith, M. D., Jin, J., Fitzgerald, K. C., Song, A., Liu, P., Lin, J.-P., et al. (2021) · Nature · doi:10.1038/s41586-021-03892-7 · Cited by 768
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766 · cited 4×
“Seven types of cortical lesions have been defined based on their localization in the brain (Kidd et al., 1999), which have been simplified to three predominant categories (Bø et al.”
BackgroundMethodInfluentialSubpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757 · cited 2×
“A fourth type of cortical lesion has also been classified with extensive demyelination across the entire cortex, but with no extension into the subpial white matter (Bø et al., 2003).”
BackgroundDistinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733 · cited 1×
“myelin proteins, such as myelin-associated glycoprotein (MAG) and proteolipoprotein (PLP), respectively (Lucchinetti et al., 1996; Prineas et al., 1984).”
BackgroundFrischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713
ISCEV standard for clinical visual evoked potentials: (2016 update)
International Society for Clinical Electrophysiology of Vision, Odom, J. V., Bach, M., Brigell, M., Holder, G. E., McCulloch, D. L., Mizota, A., & Tormene, A. P. (2016) · Documenta Ophthalmologica · doi:10.1007/s10633-016-9553-y · Cited by 699
An updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692 · cited 4×
“Although these lesions do not exhibit inflammatory activity, over time newly infiltrating immune cells induce inflammatory activity that has been observed by MRI (Campbell et al., 2012; Kuhlmann et al., 2017; Thompson et al., 1991).”
BackgroundMethodInfluentialNeurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684 · cited 1×
“Pattern III lesion borders are not well defined, with rims of myelin preserved around inflamed vessels within the demyelinated area and evidence of oligodendrocyte degradation and apoptosis (Lucchinetti et al., 2000; Zrzavy et al., 2017).”
BackgroundRejuvenation of Regeneration in the Aging Central Nervous System
Ruckh, J. M., Zhao, J.-W., Shadrach, J. L., van Wijngaarden, P., Rao, T. N., Wagers, A. J., & Franklin, R. J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.11.019 · Cited by 649
Regenerating CNS myelin — from mechanisms to experimental medicines
Franklin, R. J. M., & ffrench-Constant, C. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.136 · Cited by 647
Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02451.2002 · Cited by 625
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574 · cited 1×
“Additionally, those with progressive MS are less likely to experience remyelinated lesions, also referred to as “shadow plaques,” than those with relapsing MS (Frischer et al., 2015; Goldschmidt et al., 2009; Patrikios et al., 2006; Prineas et al., 1993).”
BackgroundMachado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
Metformin restores CNS remyelination capacity by rejuvenating aged stem cells
Neumann, B., Baror, R., Zhao, C., Segel, M., Dietmann, S., Rawji, K. S., Foerster, S., McClain, C. R., Chalut, K., van Wijngaarden, P., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.015 · Cited by 449
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.004 · Cited by 440
Remyelination capacity of the MS brain decreases with disease chronicity
Goldschmidt, T., Antel, J., König, F. B., Brück, W., & Kuhlmann, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8260a · Cited by 411 · cited 1×
“Additionally, those with progressive MS are less likely to experience remyelinated lesions, also referred to as “shadow plaques,” than those with relapsing MS (Frischer et al., 2015; Goldschmidt et al., 2009; Patrikios et al., 2006; Prineas et al., 1993).”
BackgroundDobson, R., Ramagopalan, S., Davis, A., & Giovannoni, G. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304695 · Cited by 394 · cited 1×
“Patients diagnosed with CIS who have OCBs have a greater risk of “conversion” to multiple sclerosis (Dobson et al., 2013).”
BackgroundThe contemporary spectrum of multiple sclerosis misdiagnosis
Solomon, A. J., Bourdette, D. N., Cross, A. H., Applebee, A., Skidd, P. M., Howard, D. B., Spain, R. I., Cameron, M. H., Kim, E., Mass, M. K., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003152 · Cited by 334
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
Ruano, L., Portaccio, E., Goretti, B., Niccolai, C., Severo, M., Patti, F., Cilia, S., Gallo, P., Grossi, P., Ghezzi, A., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516674367 · Cited by 331
Extensive cortical remyelination in patients with chronic multiple sclerosis
Albert, M., Antel, J., Brück, W., & Stadelmann, C. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2006.00043.x · Cited by 314 · cited 1×
“Evidence of cortical lesions are observed in both relapsing and progressive forms of MS, with lesions in the cortex or in juxtacortical positions representing approximately 20%–25% of all lesions and appearing in up to 90% of MS cases based on post-mortem analyses (Albert et al., 2007; Brownell & Hughes, 1962; Geurts…”
BackgroundDisease-specific molecular events in cortical multiple sclerosis lesions
Fischer, M. T., Wimmer, I., Höftberger, R., Gerlach, S., Haider, L., Zrzavy, T., Hametner, S., Mahad, D., Binder, C. J., Krumbholz, M., et al. (2013) · Brain · doi:10.1093/brain/awt110 · Cited by 311
Mechanisms of lysophosphatidylcholine‐induced demyelination: A primary lipid disrupting myelinopathy
Plemel, J. R., Michaels, N. J., Weishaupt, N., Caprariello, A. V., Keough, M. B., Rogers, J. A., Yukseloglu, A., Lim, J., Patel, V. V., Rawji, K. S., et al. (2018) · Glia · doi:10.1002/glia.23245 · Cited by 220
Baer, A. S., Syed, Y. A., Kang, S. U., Mitteregger, D., Vig, R., ffrench-Constant, C., Franklin, R. J. M., Altmann, F., Lubec, G., & Kotter, M. R. (2009) · Brain · doi:10.1093/brain/awn334 · Cited by 211
Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions
Gaitán, M. I., Shea, C. D., Evangelou, I. E., Stone, R. D., Fenton, K. M., Bielekova, B., Massacesi, L., & Reich, D. S. (2011) · Annals of Neurology · doi:10.1002/ana.22472 · Cited by 174
Lindner, M., Heine, S., Haastert, K., Garde, N., Fokuhl, J., Linsmeier, F., Grothe, C., Baumgärtner, W., & Stangel, M. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00879.x · Cited by 169
A comparative study of CSF neurofilament light and heavy chain protein in MS
Kuhle, J., Plattner, K., Bestwick, J. P., Lindberg, R. L., Ramagopalan, S. V., Norgren, N., Nissim, A., Malaspina, A., Leppert, D., Giovannoni, G., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513482374 · Cited by 155
Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers
Kaisey, M., Solomon, A. J., Luu, M., Giesser, B. S., & Sicotte, N. L. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.01.048 · Cited by 148
Trapp, B. D., Vignos, M., Dudman, J., Chang, A., Fisher, E., Staugaitis, S. M., Battapady, H., Mork, S., Ontaneda, D., Jones, S. E., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30245-x · Cited by 146
Singh, S., Dallenga, T., Winkler, A., Roemer, S., Maruschak, B., Siebert, H., Brück, W., & Stadelmann, C. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0831-8 · Cited by 118
Functional recovery of callosal axons following demyelination: A critical window
Crawford, D. K., Mangiardi, M., Xia, X., López-Valdés, H. E., & Tiwari-Woodruff, S. K. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.09.069 · Cited by 97
Non‐human primate models of multiple sclerosis
Brok, H. P. M., Bauer, J., Jonker, M., Blezer, E., Amor, S., Bontrop, R. E., Laman, J. D., & ‘t Hart, B. A. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1830114.x · Cited by 85
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion
Keegan, B. M., Kaufmann, T. J., Weinshenker, B. G., Kantarci, O. H., Schmalstieg, W. F., Paz Soldan, M. M., & Flanagan, E. P. (2016) · Neurology · doi:10.1212/wnl.0000000000003235 · Cited by 80 · cited 1×
“Lesions in critical locations within the corticospinal tract such as the lateral spinal cord have been associated with progressive motor impairment, attributed to few or even a single lesion (Keegan et al., 2016; Sechi et al., 2019).”
Backgroundvan den Bosch, A., Fransen, N., Mason, M., Rozemuller, A. J., Teunissen, C., Smolders, J., & Huitinga, I. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001154 · Cited by 58
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
“Axonal transection and chronic demyelination cause permanent damage, ultimately leading to neuron loss and brain atrophy, which signify neurodegeneration (Mey et al., 2023).”
BackgroundInflammation as common link to progressive neurological diseases
Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03628-8 · Cited by 60
Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis
Clayton, B. L. L., Barbar, L., Sapar, M., Kalpana, K., Rao, C., Migliori, B., Rusielewicz, T., Paull, D., Brenner, K., Moroziewicz, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.08.002 · Cited by 38
Lazzarotto, A., Hamzaoui, M., Tonietto, M., Dubessy, A.-L., Khalil, M., Pirpamer, L., Ropele, S., Enzinger, C., Battaglini, M., Stromillo, M. L., et al. (2024) · Brain · doi:10.1093/brain/awae024 · Cited by 33
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Metadata
- Authors
- Mey, G. M., Mahajan, K. R., & DeSilva, T. M.
- Venue
- WIREs Mechanisms of Disease
- Publisher
- Wiley
- Published
- 2022-08-10
- Volume
- 15
- Issue
- 1
- Pages
- e1583-e1583
- ISSN
- 2692-9368 (ISSN-L)
- OpenAlex
- W4291019740
- Cited by
- 169
- References
- 60
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.